At the operational update and release of the financial results for the third fiscal quarter ended 31 January 2023, the KalVista Pharmaceuticals, Inc. CEO Andrew Crockett says:

“We have made significant advances at KalVista over this quarter, including completing a financing that funds us into 2025, well beyond our phase 3 data results, which remain on track for the second half of this year. We continue to publish sebetralstat data across a wide variety of outlets, including influential medical journals such as The Lancet, and make presentations at prestigious medical and patient meetings. We remain committed to addressing the unmet needs of the HAE community by providing sebetralstat as a significant advancement in treatment for this disease.”
(Source: KalVista)